Enliven Therapeutics, Inc. (ELVN) › Operating IncomeEnliven Therapeutics, Inc. (ELVN) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2019: -$24.12M2020: -$41.70M2021: -$51.44M2022: -$38.79M2023: -$83.53M2024: -$104.55M2025: -$119.66M-$119.66M2019Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$119.66M-14.4%2024-$104.55M-25.2%2023-$83.53M-115.3%2022-$38.79M+24.6%2021-$51.44M-23.4%2020-$41.70M-72.9%2019-$24.12M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share